Foley Gardere is a Finalist for Two D CEO 2018 Mergers and Acquisition Awards
01 May 2018
Two deals on which Foley Gardere served as counsel are finalists for D CEO’s 2018 Mergers-and-Acquisitions Awards:
- Rosewood Private Investment’s July 2017 acquisition of Healthy Natural is nominated in the “Small Deals” category. Healthy Natural is an Irving-based contract-manufacturer and packaging company of natural products, and the acquisition increased utilization of Healthy Natural’s 50,000-square-foot state-of-the-art facility, which previously had been operating at 50 percent capacity.
- Clavis Capital Partner’s August 2017 acquisition of Azimuth Technoloy is nominated in the “Midsized Deals” category. Azimuth is a Naples, Florida-based component manufacturer for manufacturers and aftermarket distributors in the firearm and defense industries. Finding capital partners comfortable lending to or investing in the firearms business presented a challenge in this deal.
People
Related News
25 July 2024
In the News
Donald Schroeder on Groff – ‘Supreme Court decision is inviting a more fact-based analysis’
Foley & Lardner LLP partner Donald Schroeder assessed the impact of the U.S. Supreme Court’s 2023 decision in a religious accommodation case as it returns to the district court in the Law360 article, “A Year After High Court Spotlight, Groff Case Still A Bellwether.”
24 July 2024
In the News
Louis Lehot Featured in Q&A on How Startups Can Prepare for IPO
Foley & Lardner LLP partner Louis Lehot features in the Q&A, "How startups can get in top shape for an IPO, according to Silicon Valley lawyer Louis Lehot," part of Business Insider's Road to IPO' series.
24 July 2024
In the News
Courtenay Brinckerhoff on Patent Cap in Drug Pricing – ‘Hard to predict if this will make a difference’
Foley & Lardner LLP partner Courtenay Brinckerhoff discussed a recent bill passed in the U.S. Senate aimed at lowering drug prices by limiting the number of patents that can be asserted in cases over biosimilars in the Law360 article, “Patent Cap In Drug Pricing Bill Seen As Having Muted Effect.”